Haemate

Haemate is a prescription intravenous medication containing human coagulation factor VIII and human von Willebrand factor. It is supplied as a sterile solution for intravenous infusion; specific strength and dosage form are not disclosed in the summary. The product is marketed in the European Union and is used to replace deficient clotting factors in patients with hemophilia A or von Willebrand disease through therapy management protocol.

Haemate is indicated for several clinical situations involving deficiencies of factor VIII and von Willebrand factor.

- Treatment of bleeding episodes in patients with hemophilia A. - Management of all types of von Willebrand disease, including type 1, 2, and 3. - Prophylactic therapy before surgical or invasive procedures in individuals with combined factor VIII and von Willebrand factor deficiency. - Long‑term prophylaxis to reduce the frequency of spontaneous bleeds in severe hemophilia A. - Replacement therapy in patients with combined factor VIII and von Willebrand factor deficiency when on‑demand treatment is required.

Adverse reactions to Haemate have been reported; they vary in frequency and severity.

Common: - Headache - Fever or chills - Nausea or vomiting - Injection site reactions such as redness or swelling

Serious: - Development of inhibitors (antibodies) against factor VIII or von Willebrand factor - Allergic reactions including rash, urticaria, or anaphylaxis - Thromboembolic events such as deep‑vein thrombosis - Renal or hepatic dysfunction in rare cases

Before initiating Haemate, clinicians should evaluate several safety considerations to minimize risk.

- Assess for a history of inhibitors to factor VIII or von Willebrand factor. - Verify patient’s baseline liver and kidney function tests. - Use caution in patients with a known hypersensitivity to plasma‑derived products. - Monitor for signs of thrombosis, especially in individuals with cardiovascular risk factors. - Consider pregnancy status; safety data are limited. - Review concurrent anticoagulant or antiplatelet therapy. - Ensure proper storage and handling to maintain product integrity.

Haemate may interact with other medicines; some combinations should be avoided while others require careful monitoring.

Avoid: - Concomitant use of other plasma‑derived clotting factor concentrates without medical supervision. - Simultaneous administration of high‑dose pro‑coagulant agents that could increase thrombosis risk.

Use with caution: - Antifibrinolytic agents such as tranexamic acid; monitor for excessive clot formation. - Anticoagulants (e.g., warfarin, direct oral anticoagulants); adjust dosing and monitor coagulation parameters. - Immunosuppressive drugs that may affect inhibitor development. - Vaccines administered intramuscularly; observe for local reactions.